TCR-T cell therapy for MAGE-A4-positive sarcomas and other tumors
Part of Cancer clinical trials.
This trial tests a personalized cell therapy called TCR-T that targets a protein called MAGE-A4 on tumor cells. It is for people with advanced sarcomas or similar cancers that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of sarcoma or related cancer that has spread or cannot be removed with surgery, and standard treatments have stopped working.
- Your tumor must have a certain amount of the MAGE-A4 protein (measured by a test that gives an H-score of 30 or higher).
- You must have a specific immune system marker called HLA-A*02 positive (a blood test can tell this).
- You must be in fairly good general health (able to care for yourself, with adequate organ function).
- You must not have had chemotherapy or other cancer treatments within the past 3 to 4 weeks (depending on the type).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (TCR-T) designed to attack cancer cells with a specific KRAS mutation. It may be an option for people with advanced solid tumors who have run out of standard treatments.
This trial tests a new type of cell therapy called CAR-T cells that are designed to find and attack cancer cells that have a specific marker (GD2 or PSMA). It is for people whose cancer has not been controlled by standard treatment, and it aims to see if this therapy is safe and effective.
This trial tests a new type of immune therapy called MAGE-A4-directed TCR-T. It uses your own immune cells (T cells) that are modified to find and attack cancer cells that have a specific protein (MAGE-A4). It is for people with advanced solid tumors who have already tried other treatments.
This trial tests an experimental treatment called CDR404 for people with certain advanced solid tumors. It is designed for those whose tumors have a specific protein (MAGE-A4) and who have already tried other treatments. The goal is to see if the treatment is safe and effective.
This trial tests a new drug that helps your immune system find and attack cancer cells that have a specific marker (MAGE-A1). It's for people with advanced solid tumors who have run out of standard options.
This early-phase study tests a personalized immune-cell treatment (TCR-T cells) made from your own immune cells. You may qualify if you have a solid tumor that shows a specific target on tumor cells and your body type (HLA-A2) matches what the therapy needs.
Hear when a new Advanced Mesenchymal Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.